Chemomab Therapeutics' Touts Positive Data From Experimental Drug For Chronic Liver Disease
Trial Results: Chemomab Therapeutics reported positive results from the Open Label Extension of their Phase 2 Spring trial for nebokitug in primary sclerosing cholangitis (PSC), showing safety, tolerability, and improvements in liver biomarkers over 48 weeks of treatment.
Stock Performance: Following the announcement, Chemomab's stock rose by 2.59%, reflecting investor interest in the promising outcomes of the trial.
Trade with 70% Backtested Accuracy
Analyst Views on CMMB
About CMMB
About the author
Market Update: Tilray Drives After-Hours Gains as Biotech Stocks Soar
Tilray Brands Surge: Tilray Brands, Inc. saw an 11.36% increase in after-hours trading, reaching $13.53, following a one-for-ten reverse stock split and positive investor sentiment regarding its restructuring and beverage portfolio.
Valneva's Positive Trial Results: Valneva SE's stock rose by 7.22% after hours to $9.31, buoyed by favorable final data from its Phase 2 chikungunya vaccine trial, which supports future Phase 3 development plans.
Chemomab and Genenta Recovery: Chemomab Therapeutics Ltd. gained 7.66% after hours to $2.39, while Genenta Science S.p.A. climbed 12.06% to $1.58, both recovering from earlier declines and reacting to recent clinical trial updates.
Kazia and Traws Pharma Movements: Kazia Therapeutics Limited increased by 10.93% after hours to $11.57, following a presentation on its cancer treatment, while Traws Pharma, despite no new developments, edged up 8.81% to $2.54, driven by low-float trading momentum.
Top Strong Buy Stocks for October 23: MQ, GES, and Others
Zacks Rank #1 Stocks: Five stocks have been added to the Zacks Rank #1 (Strong Buy) List, including Marqeta, Guess?, The Travelers Companies, Chemomab Therapeutics, and Par Pacific Holdings, with significant increases in their earnings estimates over the past 60 days.
Quantum Computing Revolution: Quantum computing is rapidly advancing and is seen as the next major technological revolution, with major companies like Microsoft, Google, and Amazon integrating it into their infrastructure.
Investment Opportunities: Senior Stock Strategist Kevin Cook has identified seven stocks that are expected to lead in the quantum computing sector, suggesting a potential investment opportunity for those looking to capitalize on this emerging technology.
Free Stock Analysis Reports: The article offers free stock analysis reports for the highlighted companies, providing additional insights for investors interested in these stocks.
VTYX, MEDP, INBX Surge in After-Hours Trading Following Important Announcements
Ventyx Biosciences Surge: Ventyx Biosciences' shares skyrocketed over 88% after positive Phase 2 trial results for its obesity and cardiovascular risk treatment, VTX3232.
Medpace Holdings Performance: Medpace Holdings saw an 18% increase in shares following better-than-expected Q3 results and an updated fiscal year 2025 guidance.
Inhibrx Biosciences Update: Inhibrx Biosciences' shares rose over 10% as the company announced a live webcast to present topline results from its ChonDRAgon study on ozekibart for chondrosarcoma.
Other Notable Movers: Several biotech stocks, including Acumen Pharmaceuticals and SCYNEXIS, experienced significant after-hours gains, reflecting a broader positive trend in the sector.
ESPR Seeks Diversification Through Rare Liver Disease Candidate, Shares Rise
New Development Candidate: Esperion Therapeutics has nominated ESP-2001, an allosteric ATP citrate lyase inhibitor, for preclinical development aimed at treating primary sclerosing cholangitis (PSC), a rare autoimmune liver disease with no current approved treatments.
Market Potential and Financial Performance: If successful, ESP-2001 could tap into a market opportunity exceeding $1 billion annually, while Esperion's existing products, Nexletol and Nexlizet, have seen a 42% increase in U.S. sales, contributing to the company's growth amidst a rising stock price.
CDTX Shares Rise Following FDA's Breakthrough Therapy Designation for CD388 in Influenza
FDA Breakthrough Therapy Designation: Cidara Therapeutics received FDA Breakthrough Therapy designation for its candidate CD388, aimed at preventing seasonal influenza, leading to a 12.4% increase in the company's shares.
CD388's Mechanism and Efficacy: CD388 is a long-acting small molecule inhibitor that offers broad protection against seasonal and pandemic flu strains, requiring only a single injection for an entire flu season, independent of the body's immune response.
Oppenheimer Reiterates Outperform Rating for Chemomab Therapeutics and Increases Price Target to $25
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing strategies and intelligence.
Market Winning Tool: Traders utilize Benzinga Pro's resources to enhance their trading success in the stock market.
Market Update: Tilray Drives After-Hours Gains as Biotech Stocks Soar
Tilray Brands Surge: Tilray Brands, Inc. saw an 11.36% increase in after-hours trading, reaching $13.53, following a one-for-ten reverse stock split and positive investor sentiment regarding its restructuring and beverage portfolio.
Valneva's Positive Trial Results: Valneva SE's stock rose by 7.22% after hours to $9.31, buoyed by favorable final data from its Phase 2 chikungunya vaccine trial, which supports future Phase 3 development plans.
Chemomab and Genenta Recovery: Chemomab Therapeutics Ltd. gained 7.66% after hours to $2.39, while Genenta Science S.p.A. climbed 12.06% to $1.58, both recovering from earlier declines and reacting to recent clinical trial updates.
Kazia and Traws Pharma Movements: Kazia Therapeutics Limited increased by 10.93% after hours to $11.57, following a presentation on its cancer treatment, while Traws Pharma, despite no new developments, edged up 8.81% to $2.54, driven by low-float trading momentum.
Top Strong Buy Stocks for October 23: MQ, GES, and Others
Zacks Rank #1 Stocks: Five stocks have been added to the Zacks Rank #1 (Strong Buy) List, including Marqeta, Guess?, The Travelers Companies, Chemomab Therapeutics, and Par Pacific Holdings, with significant increases in their earnings estimates over the past 60 days.
Quantum Computing Revolution: Quantum computing is rapidly advancing and is seen as the next major technological revolution, with major companies like Microsoft, Google, and Amazon integrating it into their infrastructure.
Investment Opportunities: Senior Stock Strategist Kevin Cook has identified seven stocks that are expected to lead in the quantum computing sector, suggesting a potential investment opportunity for those looking to capitalize on this emerging technology.
Free Stock Analysis Reports: The article offers free stock analysis reports for the highlighted companies, providing additional insights for investors interested in these stocks.
VTYX, MEDP, INBX Surge in After-Hours Trading Following Important Announcements
Ventyx Biosciences Surge: Ventyx Biosciences' shares skyrocketed over 88% after positive Phase 2 trial results for its obesity and cardiovascular risk treatment, VTX3232.
Medpace Holdings Performance: Medpace Holdings saw an 18% increase in shares following better-than-expected Q3 results and an updated fiscal year 2025 guidance.
Inhibrx Biosciences Update: Inhibrx Biosciences' shares rose over 10% as the company announced a live webcast to present topline results from its ChonDRAgon study on ozekibart for chondrosarcoma.
Other Notable Movers: Several biotech stocks, including Acumen Pharmaceuticals and SCYNEXIS, experienced significant after-hours gains, reflecting a broader positive trend in the sector.
ESPR Seeks Diversification Through Rare Liver Disease Candidate, Shares Rise
New Development Candidate: Esperion Therapeutics has nominated ESP-2001, an allosteric ATP citrate lyase inhibitor, for preclinical development aimed at treating primary sclerosing cholangitis (PSC), a rare autoimmune liver disease with no current approved treatments.
Market Potential and Financial Performance: If successful, ESP-2001 could tap into a market opportunity exceeding $1 billion annually, while Esperion's existing products, Nexletol and Nexlizet, have seen a 42% increase in U.S. sales, contributing to the company's growth amidst a rising stock price.
CDTX Shares Rise Following FDA's Breakthrough Therapy Designation for CD388 in Influenza
FDA Breakthrough Therapy Designation: Cidara Therapeutics received FDA Breakthrough Therapy designation for its candidate CD388, aimed at preventing seasonal influenza, leading to a 12.4% increase in the company's shares.
CD388's Mechanism and Efficacy: CD388 is a long-acting small molecule inhibitor that offers broad protection against seasonal and pandemic flu strains, requiring only a single injection for an entire flu season, independent of the body's immune response.
Oppenheimer Reiterates Outperform Rating for Chemomab Therapeutics and Increases Price Target to $25
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing strategies and intelligence.
Market Winning Tool: Traders utilize Benzinga Pro's resources to enhance their trading success in the stock market.
